Paxmedica's research on low dose suramin for autism spectrum disorder accepted for publication

Tarrytown, n.y. , oct. 26, 2023 (globe newswire) -- via ibn --  paxmedica , inc. (nasdaq: pxmd ) a clinical-stage biopharmaceutical company, is excited to announce that the annals of general psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled "randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder" for publication.
PXMD Ratings Summary
PXMD Quant Ranking